Log in
Enquire now
‌

US Patent 11027000 AADC polynucleotides for the treatment of Parkinson's disease

Patent 11027000 was granted and assigned to Voyager Therapeutics on June, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Voyager Therapeutics
Voyager Therapeutics
Current Assignee
Voyager Therapeutics
Voyager Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11027000
Date of Patent
June 8, 2021
Patent Application Number
16540375
Date Filed
August 14, 2019
Patent Citations
‌
US Patent 10041090 Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
Patent Citations Received
‌
US Patent 11759506 AADC polynucleotides for the treatment of Parkinson's disease
Patent Primary Examiner
‌
Michael D Burkhart
Patent abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11027000 AADC polynucleotides for the treatment of Parkinson's disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.